CH 1504

Drug Profile

CH 1504

Alternative Names: CH-1504; MobileTrex

Latest Information Update: 27 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of South Alabama
  • Developer Chelsea Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
  • 22 Oct 2009 Interim efficacy and adverse events data from a phase II trial in Rheumatoid arthritis presented at the the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
  • 18 Mar 2009 Interim efficacy & adverse events data from a phase II trial in Rheumatoid arthritis released by Chelsea Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top